Clinical trial
Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123
NCT02739165 is registered in ClinicalTrials.gov with Asahi Kasei Therapeutics Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123
- Lead sponsor
- Asahi Kasei Therapeutics Corporation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2016
- Completion date
- December 31, 2018
- Enrollment
- 74 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.